Replies to post #141534 on Avid Bioservices Inc (CDMO)

[biopharm]

Dr. Martin Edelman: Part II : Sydney, Australia 15th World Conference on Lung Cancer

Dr. Martin Edelman: "I look forward to being involved in the upcoming Phase III trial and to seeing the potential of bavituximab in other indications and combinations," said Martin J. Edelman, M.D., Professor of Medicine at the University of Maryland Greenebaum Cancer Center

https://www.facebook.com/UMGCC/posts/10151727035615439
------------------------------------------------------------------

The Amsterdam countdown is on.....

but what may even more of a telling sign is that Peregrine has decided to "sponsor" the following event

http://wclc.iaslc.org/sponsorship-exhibits/sponsorship.html

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92348054
------------------------------------------------------------------

Now a sponsor of this event "does not" have to present anything but I do find it very interesting that Peregrines name is already out there and waiting.......

I noticed Dr. Martin Edelman will be there as well:

Sun Oct 27

08:30 - 11:30

YOUNG INVESTIGATOR & FIRST TIME ATTENDEE SESSION
incl. Breakfast and Coffee Break

Chairs: Martin Edelman, USA & Gilberto Lopes, Singapore

Planning an Academic Career in Lung Cancer - Natasha Leighl, USA
How to Present Data at a Conference - Michael Boyer, Australia
How to Write a Grant Application for the IASLC - Karen Kelly, USA
How to Get your Papers Published - James Jett, USA
Using the Published Literature Effectively - Martin Stockler, Australia
----------------------------------------------------------------

Tues Oct 29

07:00-8:00 : Medical Oncology

http://www.2013worldlungcancer.org/scientific-program/scientific_program.html

-----------------------------------------------------------------

Martin J. Edelman, MD, FACP, has been named Associate Director for Clinical Research at the University of New Mexico Cancer Center. He will be Professor of Hematology/Oncology in the Department of Internal Medicine and hold the Victor and Ruby Hansen Surface Endowed Chair in Clinical Research. In addition, he will also serve as the Medical Director for the statewide New Mexico Cancer Care Alliance.

http://connection.asco.org/Magazine/Article/ID/3642/September-2013-Member-News-Networking.aspx

-----------------------------------------------------------------

University of New Mexico Health Sciences Center

May 15, 2013

Four world-renowned cancer physicians and scientists joined the University of New Mexico Health Sciences Center and the UNM Cancer Center. They are Wadih Arap, MD, PhD, and Renata Pasqualini, PhD, experts in discovery of new cancer drugs and treatment of prostate and other advanced cancers; Martin J. Edelman, MD, FACP, expert in treatment of lung and aerodigestive cancers; and Anita Kinney, PhD, expert in cancer prevention and public health, community-based research, and cancer health disparities.

https://www.facebook.com/unmhsc/posts/10151525951151156
----------------------------------------------------------------

The way I see it.... is The University of New Mexico Cancer Center may very well be setting up for a nice early head start with expanding indications for targeting PS. "QUALITY" top scientists being added here and I'd say they all know that PS is the target.... even Dr. Edelman had the quote: "I look forward to being involved in the upcoming Phase III trial and to seeing the potential of bavituximab in other indications and combinations," said Martin J. Edelman, M.D., Professor of Medicine at the University of Maryland Greenebaum Cancer Center"

The University of New Mexico ... please keep all Fargooites out of sight.
----------------------------------------------------------------

Hope is Here: Building New Mexico's Cancer Team for the Future

Summer 2013 --- listing the 4 new additions... the full list given at the link below

Martin J. Edelman, MD, FACP: Dr. Edelman joins UNM from the University of Maryland Greenebaum Cancer Center in Baltimore. A world-renowned expert in lung cancer and cancers of the head and neck, he trained at Rensselaer Polytechnic Institute, Albany Medical College, San Diego Naval Hospital, and University of California-San Diego. He has designed and led many of the nation’s clinical trials testing new treatments for lung cancer. At UNM, he is a Professor of Medicine in the Division of Hematology/Oncology in the Department of Internal Medicine at the UNM School of Medicine. As Associate Director for Clinical Research at the UNM Cancer Center, he oversees programs to test new cancer therapies for all cancers.

Wadih Arap, MD, PhD: Dr. Arap joins UNM from the M.D. Anderson Cancer Center in Houston, where he was Distinguished Professor in Medical Oncology and Deputy Chair of the Department of Genitourinary Oncology. Trained at Memorial Sloan Kettering Cancer Center, Stanford University, and the Ludwig Institute for Cancer Research, he has won numerous awards and received international acclaim for his expertise in treating patients with advanced prostate cancer. His research, focused on the development of new cancer drugs, has led to 100 patents and five new biotechnology companies. In September, he will assume the Deputy Directorship for the UNM Cancer Center and will assume the role of Hematology/Oncology Division Chief in the Department of Internal Medicine at the UNM School of Medicine.

Renata Pasqualini, PhD: Dr. Pasqualini joins UNM from the M.D. Anderson Cancer Center in Houston, where she was an Endowed Professor of Medicine and Experimental Diagnostic Imaging. Trained at the Ludwig Institute for Cancer Research, Harvard Medical School, the Harvard-Dana Farber Cancer Institute, and the Sanford-Burnham Institute, she is an internationally renowned expert in the development of new cancer drugs. Her work garnered many awards and has led to 100 patents, five new start-up companies, and 11 clinical trials testing new cancer therapies. She was named one of the nation’s “Top 400 Inventors.” In September, she will bring this expertise in developing new cancer treatments to New Mexico as Associate Director for Translational

Anita Y. Kinney, PhD, RN: Dr. Kinney joins UNM from Huntsman Cancer Institute at the University of Utah where she was the Jon and Karen Huntsman Presidential Professor in Cancer Research and leader of the Cancer Control and Population Sciences Program. Trained at University of Pennsylvania, University of Texas School of Public Health, the National Cancer Institute, and University of North Carolina-Chapel Hill, she is a highly acclaimed international expert in cancer prevention and public health. Focused particularly on breast and colorectal cancer, she will lead New Mexico’s effort to prevent cancer, working with our communities statewide to overcome the significant disparities in cancer survival. Dr. Kinney will assume the role of Associate Director for Cancer Population Sciences in August.

http://mail-dog.com/page.html?p=0000015Fu8vnye5UsrPWmZ/3tVunWLh3CJW5t1fbp+ulwn&email=[e-mail]